iShares Biotechnology ETF
NASDAQ:IBB

  • LAST PRICE
    136.72
  • TODAY'S CHANGE (%)
    0.00 (0.00%)
  • Bid / Lots
    135.28/ 1
  • Ask / Lots
    136.84/ 1
  • Open / Previous Close
    0.00 / 136.72
  • Day Range
    ---
  • 52 Week Range
    111.83
    141.16
  • Volume
    2
  • Overall Morningstar Rating
    out of 268 funds

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Daily Premium/Discount

Bar Graph.See accessible table below
ETFs trading at a price higher than its Net Asset Value (NAV) is said to be trading at a premium, while those trading at price lower than its NAV is said to be at a discount. By showing the daily premium/discount percentage, we can see the trend in market sentiments, regarding the value of an ETF over time.

Holdings Diversification

Asset Class
US Stock		91.0%
Non-US Stock		8.9%
Cash		0.2%
Convertible		0
Non-US Bond		0
Other		0
Sectors
Healthcare99.8%
Basic Mat.0
Communication Services0
Consumer Cyclical0
Consumer Defensive0
Energy0
Financial Serv.s0
Industrials0
Real Estate0
Technology0
Utilities0
Geographic Region
United States		91.1%
Europe		3.2%
Canada		0.5%
Asia/Oceania		0.1%
Africa		0
Latin America		0
As of 2024-05-30

Top 10 Holdings

Company NamePositionAllocation
Allocation
1 Month Change
Market Value
AMGN
Amgen Inc
Long
9.2%
-0.38%
$646.4M
VRTX
Vertex Pharmaceuticals Inc
Long
8.8%
-0.38%
$619.3M
REGN
Regeneron Pharmaceuticals Inc
Long
8.4%
-0.38%
$590.4M
GILD
Gilead Sciences Inc
Long
7.4%
-0.38%
$522.7M
MRNA
Moderna Inc
Long
5.2%
-0.38%
$363.7M
IQV
IQVIA Holdings Inc
Long
4.1%
-0.38%
$285.9M
BIIB
Biogen Inc
Long
3.2%
-0.38%
$227.2M
MTD
Mettler-Toledo International Inc
Long
3.0%
-0.38%
$209.4M
BNTX
BioNTech SE ADR
Long
2.1%
-0.38%
$146.2M
ALNY
Alnylam Pharmaceuticals Inc
Long
1.9%
-0.38%
$134.6M
As of 2024-06-07

Reports

  • 08/13/16

    Morningstar ETF Report

    The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.

  • 05/12/24

    Morningstar ETF Report

    The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.

Morningstar Ratings

Time HorizonStar Rating
Overall Rating
3 Year Rating
5 Year Rating
10 Year Rating
As of 2024-05-31

Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.

Style Box is calculated only using the long position holdings of the portfolio.

ETF Profile
Best Fit Index
NYSE Biotechnology TR USD
Category
Health
Sponsor
BlackRock Fund Advisors
Inception
February 5, 2001
As of 2024-05-30

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Holding Details
Total Net Assets$7.1B
Shares Out.53.6M
Net Asset Value (NAV)$136.69
Prem/Discount to NAV0.02%
P/E Ratio25.3
Dividend Yield0.30%
Dividend per Share0.41 USD
Ex-Dividend Date03/21/2024
Dividend Payment Date03/27/2024
Beta---
Morningstar Investment StyleHealth
Equity Style
Mid Cap Blend
Credit Quality / Duration
---
Fees & Expenses
Actual Management Fee0.45%
Actual Mgmt. Expense Ratio (MER)0.45%